Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro

Journal of General Virology

Volumn 94, Issue PART 5, 2013, Pages 933-943

  Harada, Shigeyoshi ^a,b   Yoshimura, Kazuhisa ^a,b   Yamaguchi, Aki ^a   Boonchawalit, Samatchaya ^a,b   Yusa, Keisuke ^c   Matsushita, Shuzo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; INTEGRASE; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; RANTES; SAQUINAVIR; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; GENE MUTATION; GENOTYPE; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL;

EID: 84876229859     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.047167-0     Document Type: Article

References (34)

1. Anastassopoulou, C. G., Ketas, T. J., Klasse, P. J. & Moore, J. P. (2009). Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A 106, 5318-5323.
2. Berro, R., Sanders, R. W., Lu, M., Klasse, P. J. & Moore, J. P. (2009). Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 5, e1000548.
3. Charpentier, C., Nora, T., Tenaillon, O., Clavel, F. & Hance, A. J. (2006). Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol 80, 2472-2482.
4. Delwart, E. L., Pan, H., Neumann, A. & Markowitz, M. (1998). Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J Virol 72, 2416-2421.
5. Eigen, M. (1993). The origin of genetic information: viruses as models. Gene 135, 37-47.
6. Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A. & other authors (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359, 1429-1441.
7. Hatada, M., Yoshimura, K., Harada, S., Kawanami, Y., Shibata, J. & Matsushita, S. (2010). Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J Gen Virol 91, 1335-1345.
8. Hombrouck, A., Voet, A., Van Remoortel, B., Desadeleer, C., De Maeyer, M., Debyser, Z. & Witvrouw, M. (2008). Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother 52, 2069-2078.
9. Ibáñez, A., Clotet, B. & Martínez, M. A. (2000). Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J Gen Virol 81, 85-95.
10. Jacobson, J. M., Thompson, M. A., Lalezari, J. P., Saag, M. S., Zingman, B. S., D'Ambrosio, P., Stambler, N., Rotshteyn, Y., Marozsan, A. J. & other authors (2010). Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 201, 1481-1487.
11. Kitrinos, K. M., Nelson, J. A., Resch, W. & Swanstrom, R. (2005). Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol 79, 10627-10637.
12. Kobayashi, M., Nakahara, K., Seki, T., Miki, S., Kawauchi, S., Suyama, A., Wakasa-Morimoto, C., Kodama, M., Endoh, T. & Oosugi, E. (2008). Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 80, 213-222.
13. Maeda, Y., Yusa, K. & Harada, S. (2008). Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antiviral Res 77, 128-135.
14. McNicholas, P., Wei, Y., Whitcomb, J., Greaves, W., Black, T. A., Tremblay, C. L. & Strizki, J. M. (2010). Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J Infect Dis 201, 1470-1480.
15. Nájera, R., Delgado, E., Pérez-Alvarez, L. & Thomson, M. M. (2002). Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 16 (Suppl. 4), S3-S16.
16. th Conference on Retroviruses and Opportunistic Infections, abstract 49. Boston, MA.
17. Nijhuis, M., Boucher, C. A., Schipper, P., Leitner, T., Schuurman, R. & Albert, J. (1998). Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A 95, 14441-14446.
18. Nora, T., Charpentier, C., Tenaillon, O., Hoede, C., Clavel, F. & Hance, A. J. (2007). Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J Virol 81, 7620-7628.
19. Rhee, S.-Y., Liu, T. F., Kiuchi, M., Zioni, R., Gifford, R. J., Holmes, S. P. & Shafer, R. W. (2008). Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 5, 74.
20. Sheehy, N., Desselberger, U., Whitwell, H. & Ball, J. K. (1996). Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 observed during zidovudine (AZT) therapy. J Gen Virol 77, 1071-1081.
21. Shibata, J., Yoshimura, K., Honda, A., Koito, A., Murakami, T. & Matsushita, S. (2007). Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J Virol 81, 3757-3768.
22. Sing, T., Low, A. J., Beerenwinkel, N., Sander, O., Cheung, P. K., Domingues, F. S., Büch, J., Däumer, M., Kaiser, R. & other authors (2007). Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12, 1097-1106.
23. Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M. & other authors (2008). Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359, 339-354.
24. Stupple, P. A., Batchelor, D. V., Corless, M., Dorr, P. K., Ellis, D., Fenwick, D. R., Galan, S. R., Jones, R. M., Mason, H. J. & other authors (2011). An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propylacetamide (PF- 232798). J Med Chem 54, 67-77.
25. Tamura, K., Dudley, J., Nei, M. & Kumar, S. (2007). MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24, 1596-1599.
26. Tilton, J. C., Wilen, C. B., Didigu, C. A., Sinha, R., Harrison, J. E., Agrawal-Gamse, C., Henning, E. A., Bushman, F. D., Martin, J. N. & other authors (2010). A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both Nterminal and extracellular loop domains of drug-bound CCR5. J Virol 84, 10863-10876.
27. Toma, J., Weinheimer, S. P., Stawiski, E., Whitcomb, J. M., Lewis, S. T., Petropoulos, C. J. & Huang, W. (2011). Loss of asparaginelinked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol 85, 3872-3880.
28. Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. (2006). Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344-348.
29. Yoshimura, K., Shibata, J., Kimura, T., Honda, A., Maeda, Y., Koito, A., Murakami, T., Mitsuya, H. & Matsushita, S. (2006). Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 20, 2065-2073.
30. Yoshimura, K., Harada, S., Hatada, M. & Matsushita, S. (2009). Mutations in V4 and C4 regions of the HIV-1 CRF08-BC envelope induced by the in vitro selection of Maraviroc Confer cross-resistance to other CCR5 inhibitors. In 16th Conference on Retroviruses and Opportunistic Infections, p. 640. Montreal, Canada.
31. Yoshimura, K., Harada, S. & Matsushita, S. (2010a). Two step escape pathway of the HIV-1 subtype C primary isolate induced by the in vitro selection of Maraviroc. In 17th Conference on Retroviruses and Opportunistic Infections, abstract 535. San Francisco, CA.
32. Yoshimura, K., Harada, S., Shibata, J., Hatada, M., Yamada, Y., Ochiai, C., Tamamura, H. & Matsushita, S. (2010b). Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 84, 7558-7568.
33. Yusa, K., Maeda, Y., Fujioka, A., Monde, K. & Harada, S. (2005). Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 280, 30083-30090.
34. Zhang, Y. M., Dawson, S. C., Landsman, D., Lane, H. C. & Salzman, N. P. (1994). Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J Virol 68, 425-432.